Large‐scale expansion of cytomegalovirus‐specific cytotoxic T cells in suspension culture

Clinical trials in recent years involving the adoptive transfer of antigen‐specific cytotoxic T lymphocytes (CTL) have shown promise in restoring immunity against viral infection and reducing tumor burden in patients with solid and hematological malignancies. However, the large cell number required to achieve efficacy, 109 to 1011, makes routine application of adoptive immunotherapy impractical. Investigation into new methods of CTL expansion may be useful in addressing this problem. Use of stirred suspension bioreactors are one such method that may allow large‐scale T‐cell expansion. Suspension cultures offer advantages over conventional static culture methods, including providing a homogeneous culture environment, and the potential for optimization and control of culture conditions. We generated cytomegalovirus (CMV)‐specific CTL and investigated the potential of stirred bioreactor systems for expansion of large cell numbers. We found that CTL can be readily expanded ( > 200‐fold) from cryopreserved stocks by nonspecific stimulation in the presence of allogeneic feeder cells and interleukin‐2 (IL‐2). Activated CTL inoculated into either suspension or static cultures could be subsequently expanded tenfold, and showed similar growth kinetics and metabolism independent of the culture vessel used. Furthermore, CTL remained specific for CMVpp65 peptide through the expansion phases, as demonstrated by pp65–tetramer staining ( > 95% tetramer+) and cytotoxicity assays. This study indicates that suspension reactor systems may be useful in large‐scale expansion of antigen‐specific CTL lines or clones, and may facilitate the advancement of routine adoptive immunotherapy. © 2003 Wiley Periodicals, Inc.

[1]  Craig W. Reynolds,et al.  A closed culture system for the ex vivo transduction and expansion of human T lymphocytes. , 1998, Journal of hematotherapy.

[2]  M. Davis,et al.  A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. , 1999, Cancer research.

[3]  J. Miller,et al.  Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor. , 1996, Journal of hematotherapy.

[4]  D. Srivastava,et al.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.

[5]  E. Papoutsakis,et al.  Culture of human T cells in stirred bioreactors for cellular immunotherapy applications: Shear, proliferation, and the IL‐2 receptor , 2000, Biotechnology and bioengineering.

[6]  A. Bosi,et al.  Selective ex vivo expansion of cytomegalovirus‐specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201‐restricted peptide , 2001, British journal of haematology.

[7]  S. Riddell,et al.  The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. , 1999, Journal of immunology.

[8]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[9]  T. Noll,et al.  Bioprocess development for the cultivation of human T-lymphocytes in a clinical scale , 2004, Cytotechnology.

[10]  N. Hensel,et al.  Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. , 2001, Blood.

[11]  E. Atkinson,et al.  Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. , 1994, Journal of immunological methods.

[12]  S. Riddell,et al.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. , 1992, Science.

[13]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[14]  S. Fujita,et al.  HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. , 2000, Blood.

[15]  J L Riley,et al.  Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. , 1998, Journal of hematotherapy.

[16]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[17]  Mark M. Davis,et al.  Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma , 2000, The Journal of experimental medicine.

[18]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Romagnoli,et al.  Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy. , 2003, Journal of hematotherapy & stem cell research.

[20]  J. York,et al.  Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. , 1997, Blood.

[21]  W M Miller,et al.  Characterization of Hematopoietic Cell Expansion, Oxygen Uptake, and Glycolysis in a Controlled, Stirred‐Tank Bioreactor System , 1998, Biotechnology progress.

[22]  Richard E. Slaughter,et al.  Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Riddell,et al.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus‐specific cytotoxic T lymphocytes , 1994, Journal of medical virology.

[24]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.